Proprietary AI analyst is now available
- Public Comps
- HeartSciences
HeartSciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for HeartSciences and similar public comparables like Genomed, CurveBeam AI, Ayfie International, Biomaxima and more.
HeartSciences Overview
About HeartSciences
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
Founded
2007
HQ

Employees
24
Website
Financials (LTM)
EV
$10M
Valuation Multiples
Start free trialHeartSciences Financials
HeartSciences reported last 12-month revenue of $111K and negative EBITDA of ($8M).
In the same LTM period, HeartSciences generated $64K in gross profit, ($8M) in EBITDA losses, and had net loss of ($9M).
HeartSciences P&L
In the most recent fiscal year, HeartSciences reported revenue of $4K and EBITDA of ($8M).
HeartSciences is unprofitable as of last fiscal year, with gross margin of 57%, EBITDA margin of (182759%), and net margin of (201500%).
Financial data powered by Morningstar, Inc.
HeartSciences Stock Performance
HeartSciences has current market cap of $10M, and enterprise value of $10M.
HeartSciences' stock price is $2.90.
HeartSciences has an EPS (earnings per share) of $-2.66.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10M | $10M | -2.5% | - | - | - | $-2.66 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHeartSciences Valuation Multiples
HeartSciences trades at 90.0x EV/Revenue multiple, and (1.2x) EV/EBITDA.
HeartSciences Financial Valuation Multiples
As of June 27, 2026, HeartSciences has market cap of $10M and EV of $10M.
HeartSciences has a P/E ratio of (1.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified HeartSciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


HeartSciences Margins & Growth Rates
HeartSciences decreased revenue by 100% and EBITDA by 1% in the last fiscal year.
In the most recent fiscal year, HeartSciences reported gross margin of 57%, EBITDA margin of (182759%), and net margin of (201500%).
HeartSciences Margins
HeartSciences Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
HeartSciences Operational KPIs
HeartSciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.
HeartSciences' Rule of 40 is 30148% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
HeartSciences' Rule of X is 78274% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
HeartSciences Competitors
HeartSciences competitors include Genomed, CurveBeam AI, Ayfie International, Biomaxima, Predilife, Synthetic MR, Immunovia, Baseig, OODA AI and Genetic Analysis.
Most HeartSciences public comparables operate across Medical Imaging & Diagnostics, Pure-Play AI Software, HealthTech, Generative AI and Longevity.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.0x | - | 5.8x | - | |||
| 2.2x | 2.3x | (2.5x) | (2.5x) | |||
| 5.0x | - | (2.6x) | - | |||
| 1.1x | 0.8x | 12.0x | 7.5x | |||
| 22.6x | - | (3.5x) | - | |||
| 0.4x | 0.4x | (1.0x) | (1.7x) | |||
| 66.5x | 35.5x | (0.9x) | (0.8x) | |||
| 11.4x | - | 19.3x | - | |||
This data is available for Pro users. Sign up to see all HeartSciences competitors and their valuation data. Start Free Trial | ||||||
HeartSciences VC Funding History
Before going public, HeartSciences raised $23M in total equity funding, across 3 rounds.
HeartSciences Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout HeartSciences
| When was HeartSciences founded? | HeartSciences was founded in 2007. |
| Where is HeartSciences headquartered? | HeartSciences is headquartered in United States. |
| How many employees does HeartSciences have? | As of today, HeartSciences has over 24 employees. |
| Is HeartSciences publicly listed? | Yes, HeartSciences is a public company listed on Nasdaq. |
| What is the stock symbol of HeartSciences? | HeartSciences trades under HSCS ticker. |
| When did HeartSciences go public? | HeartSciences went public in 2022. |
| Who are competitors of HeartSciences? | HeartSciences main competitors include Genomed, CurveBeam AI, Ayfie International, Biomaxima, Predilife, Synthetic MR, Immunovia, Baseig, OODA AI, Genetic Analysis. |
| What is the current market cap of HeartSciences? | HeartSciences' current market cap is $10M. |
| What is the current revenue of HeartSciences? | HeartSciences' last 12 months revenue is $111K. |
| What is the current revenue growth of HeartSciences? | HeartSciences revenue growth (NTM/LTM) is 529%. |
| What is the current EV/Revenue multiple of HeartSciences? | Current revenue multiple of HeartSciences is 90.0x. |
| Is HeartSciences profitable? | No, HeartSciences is not profitable. |
| What is the current EBITDA of HeartSciences? | HeartSciences has negative EBITDA and is not profitable. |
| What is HeartSciences' EBITDA margin? | HeartSciences' last 12 months EBITDA margin is (7345%). |
| What is the current EV/EBITDA multiple of HeartSciences? | Current EBITDA multiple of HeartSciences is (1.2x). |
| How many companies HeartSciences has acquired to date? | HeartSciences hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies HeartSciences has invested to date? | HeartSciences hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to HeartSciences
Lists including HeartSciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.